Truist lowered the firm's price target on Maze Therapeutics to $64 from $68 and keeps a Buy rating on the shares. The firm has updated its outlook following the company's 10-K filing, revising its operating expense assumptions and updating its share count to reflect outstanding pre-funded warrants, the analyst tells investors in a research note.
